Abingdon Life Sciences has entered into an agreement with Stason Pharmaceuticals, to provide clinical and regulatory support for Stason's drug development programmes. As part of the agreement, Abingdon will provide clinical and regulatory services for Stason's pipeline of potential drug candidates and devices in the areas of cancer and inflammation.

"We are extremely happy to have formalized our relationship with Stason, and believe that this represents a synergistic opportunity for both our companies to leverage our respective core competencies in drug development and manufacturing," said Richard Lebovitz, Abingdon CEO. Harry Fan, CEO of Stason added "Stason is pleased to have agreed to this strategic partnership with Abingdon. It is a mutually beneficial relationship bringing expertise in many areas to our clients, both here in the US and in our overseas markets."

Abingdon Life Sciences is a first-in-class Drug and Device Development Management Organization (DDMO) providing drug and device companies superior clinical and regulatory services based on an integrated strategic development model.

Founded in 1994, Stason Pharmaceuticals has evolved into a vertically integrated cGMP contract development organization with affiliates and locations in Texas, Massachusetts, Japan, China and Taiwan that provide complete turn-key drug development solutions for API, prototype and final product, clinical supplies for all phases, and commercial production and distribution.